SCHEDULE 13D/A: Major Shareholder GKCC Increases Stake in Elicio Therapeutics, Provides $10 Million Senior Secured Note

GKCC, LLC and its manager Yekaterina Chudnovsky have increased their beneficial ownership in Elicio Therapeutics, Inc. to 48% through the issuance of new warrants and a $10 million senior secured promissory note.

Summary

• GKCC, LLC and Yekaterina Chudnovsky now beneficially own approximately 48% of Elicio Therapeutics, Inc.'s Common Stock.
• This ownership includes 5,416,212 shares held directly by GKCC, 2,632,702 shares underlying Pre-Funded Warrants, 1,703,225 shares underlying Common Warrants, and 12,725 shares held directly by Ms. Chudnovsky.
• On June 3, 2025, Elicio Therapeutics issued GKCC warrants (2025 Warrants) to purchase up to 103,225 additional shares of Common Stock at an exercise price of $7.75, exercisable until June 3, 2030.
• These 2025 Warrants were issued in connection with a Senior Secured Promissory Note of $10.0 million provided by GKCC to Elicio Therapeutics, due June 3, 2028.
• The beneficial ownership percentage is calculated based on 15,996,976 shares outstanding as of May 9, 2025, plus exercisable warrants.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company secured $10 million in financing, which is crucial for operations, it comes with new debt and potential dilution from warrants. The increased stake by a major shareholder can be seen as a vote of confidence, but also increases ownership concentration.

Positives

• Elicio Therapeutics secured $10.0 million in financing through a Senior Secured Promissory Note, providing crucial capital for operations and development.
• A major shareholder, GKCC, demonstrates continued commitment and confidence in the company by increasing its stake and providing significant funding.

Negatives

• The issuance of warrants and the potential exercise of existing warrants could lead to dilution for existing shareholders.
• The company has taken on $10.0 million in new debt, which will require repayment and interest payments, adding to its financial obligations.

Risks

• Dilution Risk: The exercise of the newly issued 2025 Warrants, along with existing Pre-Funded and Common Warrants, could dilute the ownership percentage of other shareholders.
• Debt Repayment Risk: Elicio Therapeutics is obligated to repay the $10.0 million Senior Secured Promissory Note by June 3, 2028, which could strain financial resources if not managed effectively.
• Concentrated Ownership Risk: GKCC and Yekaterina Chudnovsky's significant beneficial ownership (48%) could give them substantial influence over company decisions, potentially limiting the influence of other shareholders.

Future Outlook

The document primarily reports a change in beneficial ownership and a financing transaction. It does not contain explicit forward-looking statements or guidance regarding future company performance, strategic plans, or financial projections beyond the maturity date of the note and warrant expiry.

Industry Context

This filing indicates a capital infusion for Elicio Therapeutics, a biotechnology company. In the biotech industry, securing financing is crucial for funding research and development, clinical trials, and operational continuity, especially for companies that may not yet have commercialized products. The structure of debt with warrants is a common financing mechanism for early to mid-stage biotech firms to raise capital.

Related Party Transactions

• The transaction involves Elicio Therapeutics issuing a Senior Secured Promissory Note and 2025 Warrants to GKCC, LLC, which is a significant beneficial owner (48%) of the Issuer's Common Stock. Yekaterina Chudnovsky, who has sole voting and investment control over GKCC, LLC, is also a beneficial owner. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for dilution from the exercise of new and existing warrants. However, the capital infusion may support company operations and potentially enhance long-term value.
• Creditors: GKCC, LLC becomes a significant creditor with a $10.0 million Senior Secured Promissory Note.
• Company (Elicio Therapeutics): Receives $10.0 million in capital, which can be used for operations, research, and development, but incurs new debt obligations.

Next Steps

• Elicio Therapeutics will need to manage the repayment of the $10.0 million Senior Secured Promissory Note by June 3, 2028.
• GKCC, LLC has the option to exercise the 2025 Warrants at an exercise price of $7.75 at any time after June 3, 2025, until their expiration on June 3, 2030, subject to beneficial ownership limitations.

Key Dates

Recommendation

Keywords

Elicio Therapeutics, GKCC, Yekaterina Chudnovsky, Schedule 13D, Beneficial Ownership, Warrants, Promissory Note, Senior Secured Debt, Capital Raise, Biotechnology, SEC Filing, Shareholder Stake, Dilution